• 1
    Korn JH. Pathogenesis of systemic sclerosis. In: KoopmanWJ, editor. Arthritis and allied conditions. Baltimore: Williams & Wilkins, 2001. p. 164354.
  • 2
    Wigley FM, Flavahan N. Raynaud's phenomenon. Rheum Dis Clin North Am 1996; 22: 76581.
  • 3
    Desai R, Korn JH. Diagnosis and management of Raynaud phenomenon. J Musculoskel Med 2003; 20: 12435.
  • 4
    Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4: 35168.
  • 5
    Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension 1988; 12: 53048.
  • 6
    Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99104.
  • 7
    Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25: 3147.
  • 8
    Yanagisawa M, Inoue A, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J Cardiovasc Pharmacol 1989; 13 Suppl 5: S13–8.
  • 9
    Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86: 28637.
  • 10
    Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol 1989; 13 Suppl 5:S138–42.
  • 11
    Clozel M, Fischli W, Guilly C. Specific binding of endothelin on human vascular smooth muscle cells in culture. J Clin Invest 1989; 83: 175861.
  • 12
    Biondi ML, Marasini B, Bassani C, Agostoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991; 324: 113940.
  • 13
    Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992; 19: 156671.
  • 14
    Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991; 34: 97883.
  • 15
    McGregor AR, Watson A, Yunis E, Pandey JP, Takehara K, Tidwell JT, et al. Familial clustering of scleroderma spectrum disease. Am J Med 1988; 84: 102332.
  • 16
    Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998; 31 Suppl 1: S360–3.
  • 17
    Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48: 11909.
  • 18
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896903.
  • 19
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 20
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 21
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 22
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 241020.
  • 23
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 237280.
  • 24
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, la Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 25
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199206.
  • 26
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 140714.
  • 27
    Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298: 5614.
  • 28
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 42534.